Rapid Point-of-care Diagnostics

Answers at the Point of Triage™

The HEMEMICS platform empowers healthcare providers to rapidly identify infectious disease pathogens in 60 seconds or less and generate real-time alerts to an outbreak.

Our novel multiplexed immuno-biosensor could provide rapid detection of COVID-19 anywhere in the world.

Rapid, cost-effective and real-time biomarker measurements are essential for quick and effective diagnosis and treatment of emerging diseases like COVID-19.

HEMEMICS has developed a diagnostic test platform that can yield sensitive, selective, and measurable signals in response to specific antibodies and antigens in 60 seconds or less with a single nasal swab or drop of blood. Testing is simple and could be administered by any health care worker, anywhere: ambulances, emergency rooms, community clinics and makeshift hospitals.

Most importantly, this Bluetooth® connected technology transmits the test results to a cloud-based data management network, enabling real-time geographical alerts of outbreaks or travel screening at airports, borders and transportation terminals.



HEMEMICS answers the call from US government agency R&D requests

HEMEMICS is partnering with the Biomedical Advanced Research and Development Authority (BARDA)* to produce and scale this cellphone-sized, networked, immuno-biosensor platform to detect SARS-CoV-2. BARDA wants  HEMEMICS' multiplexed technology employed to determine who has active infections and who has produced antibodies against it. This vital information can help many people to return to daily living.


*BARDA is an office of the US Department of Health and Human Services

On March 11, 2020, the CDC announced that it is currently seeking R&D contracts to:

Better understand the immune response and transmission dynamics of the SARS CoV-2 virus

Improve diagnostic testing for COVID-19, the disease caused by the virus

HEMEMICS is aggressively responding to this need with faster testing technology to address this public health emergency. This easy-to-use, easy-to-read diagnostic device can identify COVID-19 via detection of antibodies Immunoglobulin G (IgG), Immunoglobulin M (IgM) and viral particles in infected individuals.

A Significant Advantage for Clinicians and Healthcare Workers

The proprietary HEMEMICS Biosensor system can simultaneously test for up to 17 different pathogens using a single drop of blood or nasal swab. The handheld reader and test chips are small enough to be easily carried in a pocket, allowing POC diagnosis anywhere.

Delivering results in 60 seconds or less allows clinicians to test, diagnose and treat in one patient interaction.

Real-time virus detection and outbreak mapping with the HEMEMICS platform could spell the difference between accelerating or blunting the spread of an epidemic.

For more information on how HEMEMICS’ biosensor works, watch the videos below.



How HEMEMICS’ Technology Is Changing Healthcare

Results in 60 seconds


How HEMEMICS' Technology Works


Patented Preservative Makes the HEMEMICS “ChipLab” Possible


Our patented HEMSOL™ solution preserves antibodies conjugated with carbon nanotubes on the chip.


This extends shelf life of the antibodies on the chip – NO refrigeration is needed.


HEMEMICS’ proprietary platform – protected by 3 issued patents – liberates diagnostic testing from the central lab. This makes it possible and cost-effective to perform tests at the bedside or in the field for nearly instant answers.


To find out more about how the HEMEMICS technology can uniquely address COVID-19 and other diagnostic challenges, contact us.


HEMEMICS Biotechnologies, Inc.
401 Professional Drive, Suite 220
Gaithersburg, MD 20879-3445

Copyright © HEMEMICS Biotechnologies, Inc.